An analysis of the pharmaceutical industry's extensive lobbying and campaign contributions, as reported by OpenSecrets, which indicates significant influence over U.S. policy. Although CNS Pharmaceuticals is not individually spotlighted, its membership in an industry characterized by high lobbying expenditures raises concerns regarding its potential complicity in practices that favor corporate over public interests.

The Roosevelt Institute issue brief critiques how the pharmaceutical industry, through practices such as excessive lobbying, revolving door appointments, and targeted campaign contributions, is capturing governmental policymaking to prioritize profits over public health. This event raises concerns about the ethical and political practices within the industry, which by extension may be relevant to CNS Pharmaceuticals, Inc.